Synergy Between Physical Activity and Outdoor Green Environments to Reduce the Intensity of Negative Symptoms in Schizophrenia.
SAPIN
2 other identifiers
interventional
45
1 country
1
Brief Summary
Physical activity appears to be a novel and original adjunctive therapeutic approach in the management of patients with schizophrenia. It may help reduce schizophrenic symptoms, act as a pro-cognitive therapy, improve quality of life, and reduce cardiovascular comorbidities. Moreover, some evidence suggests that physical activity practiced in a natural environment has even more positive effects on mental health compared to physical activity carried out indoors or in urban settings. Indeed, greater exposure to greenery is associated with a better perception of general health and with reduced levels of cortisol, anxiety, and depression. No study has yet attempted to examine the impact of physical activity in green (outdoor) spaces compared to indoor physical activity on the negative symptoms of patients suffering from schizophrenia. The aim of this study is therefore to test this hypothesis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Oct 2025
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 30, 2025
CompletedFirst Posted
Study publicly available on registry
July 10, 2025
CompletedStudy Start
First participant enrolled
October 7, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2027
November 25, 2025
November 1, 2025
1.6 years
June 30, 2025
November 20, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Self-evaluation of negative symptoms (SNS) questionnaire
The primary outcome will be the evolution of negative symtoms, assessed using the Self-evaluation of negative symptoms (SNS) questionnaire. The total SNS score ranges from 0 to 40, where higher scores indicate greater severity of negative symptoms.
Weeks 2, 10 and 22
Secondary Outcomes (9)
Clinical global Impression (CGI) scale
Weeks 2, 10 and 22
Personal and social performance (PSP) scale
Weeks 2, 10 and 22
Subjective Scale to Investigate Cognition in Schizophrenia (SSTICS)
Weeks 2, 10 and 22.
VO2 max
Weeks 2, 10 and 22.
Maximum force
Weeks 2, 10 and 22.
- +4 more secondary outcomes
Study Arms (3)
INT group
EXPERIMENTAL8-week indoor physical activity program (in a gymnasium)
EXT group
EXPERIMENTAL8-week outdoor physical activity program
TEM group
NO INTERVENTIONWithout physical activiy program (no change in routine)
Interventions
EXT group will perform aerobic and resistance exercises with a coach in adapted physical activities on a green environment in a parc. Sessions will be typically composed as follows: * Warm-up (20 min) * Aerobic exercise (30 min) at RPE 4 to 7 on the Borg scale * Muscular strengthening (25 min) at RPE 4 to 7 on the Borg scale * Cool-down, stretching and balance (15 min) EXR group will train for 8 weeks, twice a week for 1h30, following WHO recommendation.
INT group will perform aerobic and resistance exercises with a coach in adapted physical activities, inside a conventional gym. Sessions will be typically composed as follows: * Warm-up (20 min) * Aerobic exercise (30 min) at RPE 4 to 7 on the Borg scale * Muscular strengthening (25 min) at RPE 4 to 7 on the Borg scale * Cool-down, stretching and balance (15 min) INT group will train for 8 weeks, twice a week for 1h30, following WHO recommendation.
Eligibility Criteria
You may qualify if:
- Patients with schizophrenia, aged 18 to 55 years
- Having persistent negative symptoms (SNS), negative symptoms self-assessment scale \> 7
- Regularly monitored in the psychiatry department.
- Have no medical contraindications to physical activity
- Subject affiliated with or entitled to a social security system.
- Subject having received informed information about the study and having co-signed, with the investigator, consent to participate in the study.
- Male or female.
You may not qualify if:
- Patient unsuitable for study in the opinion of the investigator
- Any subject with chronic joint pathologies (example: repeated sprains, patellar or ligament problems) or cardiac pathologies.
- Any subject presenting chronic or central neurological pathologies.
- Any subject deprived of liberty or subject to legal protection
- Excessive consumption of alcohol (\> 14 glasses per week) or caffeinated drinks (\> 400 mg of coffee per day).
- Pregnant women.
- Subject unable to understand the purpose and conditions of the study, unable to give consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU de Saint-Etienne
Saint-Etienne, France, 42055, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Medhi HOUSNI, Md
CHU de Saint-Etienne
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 30, 2025
First Posted
July 10, 2025
Study Start
October 7, 2025
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
December 1, 2027
Last Updated
November 25, 2025
Record last verified: 2025-11
Data Sharing
- IPD Sharing
- Will not share